Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors

The global emergency caused by COVID-19 makes the discovery of drugs capable of inhibiting SARS-CoV-2 a priority, to reduce the mortality and morbidity of this disease. Repurposing approved drugs can provide therapeutic alternatives that promise rapid and ample coverage because they have a documente...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Alberto, Alicia, Ribas-Aparicio, Rosa María, Aparicio-Ozores, Gerardo, Castelán-Vega, Juan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316061/
https://www.ncbi.nlm.nih.gov/pubmed/32623357
http://dx.doi.org/10.1016/j.compbiolchem.2020.107325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316061/
https://www.ncbi.nlm.nih.gov/pubmed/32623357
http://dx.doi.org/10.1016/j.compbiolchem.2020.107325

Ejemplares similares